Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Open Label Expanded Access-Program of Pegylated Interferon Alfa-2a (Pegasys) in Patients With Chronic Myelogenous Leukemia (CML)

NCT02736721 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02736721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02736721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Open Label Expanded Access-Program of Pegylated Interferon Alfa-2a (Pegasys) in Patients With Chronic Myelogenous Leukemia (CML)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2003
Completion date
November 30, 2010
Enrollment
41 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

myelogenous leukemia, chronic